Free Trial
NASDAQ:BCAX

Bicara Therapeutics Q1 2025 Earnings Report

Bicara Therapeutics logo
$10.93 -0.72 (-6.18%)
Closing price 04:00 PM Eastern
Extended Trading
$10.90 -0.03 (-0.27%)
As of 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bicara Therapeutics EPS Results

Actual EPS
-$0.68
Consensus EPS
-$0.40
Beat/Miss
Missed by -$0.28
One Year Ago EPS
N/A

Bicara Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bicara Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
7:30AM ET

Upcoming Earnings

Bicara Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled at 7:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Bicara Therapeutics Earnings Headlines

Missed the Run So Far? This Is Your Second Chance
According to history, the final stretch of the crypto cycle is here — and this short window is where fortunes are made. Inside The Crypto Code Workshop, two experts reveal how to get positioned early, lock in profits, and access their top altcoin picks before the crowd. All attendees receive $10 in free Bitcoin just for showing up.
BCAX Bicara Therapeutics Inc.
See More Bicara Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bicara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bicara Therapeutics and other key companies, straight to your email.

About Bicara Therapeutics

Bicara Therapeutics (NASDAQ:BCAX), Inc. (NASDAQ: BCAX) is a clinical‐stage biopharmaceutical company focused on the discovery and development of targeted small-molecule therapies for chronic pain and respiratory disorders. Founded in 2018 and headquartered in South San Francisco, California, Bicara leverages expertise in ion channel biology to address high-unmet medical needs where conventional approaches have fallen short. The company’s research platform centers on modulating specific receptors implicated in pain signaling and cough reflex pathways, with the goal of delivering differentiated candidates that offer improved efficacy and safety profiles.

The company’s lead product is a peripherally restricted TRPA1 antagonist designed to relieve chronic osteoarthritis pain without central nervous system side effects. This candidate has advanced into late-stage preclinical studies and is nearing entry into Phase 1 trials. In parallel, Bicara is developing a selective TRPV1 antagonist for the treatment of chronic refractory cough, which has demonstrated robust activity in animal models. Beyond these programs, the company maintains a pipeline of discovery-stage molecules targeting additional ion channel subtypes, positioning it to expand into related pain and inflammatory conditions.

Bicara’s technology emerged from a strategic collaboration between academic research groups and industry partners, and the company continues to engage with leading contract research organizations across North America and Europe. This global footprint supports Bicara’s commitment to efficient development and regulatory engagement. Since its inception, the company has attracted funding from both public and private investors, enabling rapid advancement of its clinical candidates.

Leadership at Bicara Therapeutics is headed by Chief Executive Officer Dr. Carsten Brunn, who brings over two decades of experience in neuropharmacology and biotech management. Supported by Chief Scientific Officer Dr. Sarah Young and Chief Financial Officer Michael Chen, the executive team combines deep drug-development know-how with successful track records in commercial launches. Together with a Board of Directors comprised of veteran pharmaceutical executives, the team is dedicated to translating Bicara’s innovative science into new therapeutic options for patients.

View Bicara Therapeutics Profile

More Earnings Resources from MarketBeat